Cullinan Therapeutics, INC 10-Q quarterly reports

Cullinan Therapeutics reports continued clinical development across its immunology and oncology pipelines, alongside significant operating losses and a cash runway extending through at least the next twelve months.

Cullinan Therapeutics reports Q1 2026 results, with a net loss of $49.7 million and cash reserves projected to fund operations for at least 12 months.

Cullinan Therapeutics reported a wider net loss in Q3 2025, driven by increased R&D expenses including a $20 million license fee for velinotamig, while advancing key oncology and immunology programs and discontinuing others.

Cullinan Therapeutics reported increased Q2 losses driven by higher R&D expenses, including a new $20 million license, while advancing its clinical pipeline with positive zipalertinib data and new autoimmune programs.

Cullinan Therapeutics announces its financial results for the first quarter of 2025, highlighting progress in its clinical programs and providing an update on its financial position.

Cullinan Therapeutics reported its financial results for the third quarter of 2024, highlighting progress in its clinical programs and a strong cash position.

Cullinan Therapeutics reported its financial results for the second quarter of 2024, highlighting progress in its clinical programs and a recent private placement that raised $262.7 million.

Cullinan Therapeutics reported a net loss of $37.3 million for the first quarter of 2024, while highlighting progress in its clinical programs and a recent $280 million private placement.